NCT06569511Completed
Predictive Value of NT-proBNP on MACEs After Acute Coronary Syndrome
Predictive Value of NT-proBNP on Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome During a 6-month Follow-up
Source: ClinicalTrials.gov · Last updated 26 Aug 2024
Brief summary (registry, in English)
The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a cardiac biomarker in predicting short-term major adverse cardiovascular events (MACEs) in patients with Acute coronary syndrome (ACS) has been insufficiently reported and remains poorly understood. Additionally, the relationship between NT-proBNP levels and specific ACS subtypes has not been thoroughly examined. Therefore, our study investigated the predictive value of high-sensitivity cardiac troponin (hs-cTn) and NT-proBNP levels on admission for 6-month MACEs in patients who presented to the emergency department (ED) with ACS and subsequently underwent percutaneous coronary intervention (PCI). Furthermore, we sought to evaluate the association between MACEs and specific ACS subtypes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 241 (actual)
- First submitted
- 21 Aug 2024
- Start date
- 1 Sept 2023
- Primary completion date
- 1 Feb 2024
- Lead sponsor
- Haseki Training and Research Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT06569511
What you commit to
- Study type: Observational
- Participants enrolled: 241
- From 1 Sept 2023 to the primary completion date, 1 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients had infective or structural cardiac pathologies (myocarditis, pericarditis, hypertrophic or dilated cardiomyopathies)
- patients had a diagnosis of malignancy, chronic renal failure, chronic liver failure, and a history of multiple trauma or surgery within the last month
Lab values
- patients had chronic heart failure with LVEF \<40%, class 3 and 4 in the Killip classification
Age
- patients younger than 18 years
Other
- patients had no vascular lesions detected on percutaneous coronary intervention,
Who the study is looking for
- Adult patients (≥18 years old) who were admitted to the emergency department with Acute coronary syndrome and underwent percutaneous coronary intervention between September 2023 and February 2024.
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haseki Training and Research Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.